Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Inspire Medical Systems (INSP) stock in plain English

Free brief · no signupStart here
INSPPublished Nov 14, 2026
Inspire Medical Systems Inc
Healthcare · Medical Devices
Sells an implantable neurostimulation system designed to treat obstructive sleep apnea. Provides a remote control and sensing lead that monitors breathing patterns during sleep.
Assets:
Inspire systemneurostimulator generator with breathing sensors
1,000+ employeesdirect sales and clinical support staff
1,200+ surgical centerstrained medical facilities performing implants
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

72
OPS ScoreOperating finances
Latest quote
-3.15%$56.28
$1.63B
16.4×
$881.19M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was INSP. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Inspire Medical Systems (INSP) do?

Inspire Medical Systems Inc (INSP) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells an implantable neurostimulation system designed to treat obstructive sleep apnea. Provides a remote control and sensing lead that monitors breathing patterns during sleep. Builds surgically implanted neurostimulation devices that stimulate the hypoglossal nerve to treat obstructive sleep. It is worth $1.63B on the market and sold $881.19M over the last year.

Market cap
$1.63B
P/E ratio
16.4×
Annual sales
$881.19M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 14, 2026

Brands and businesses behind INSP

  • Inspire Sleep: Sells an implantable neurostimulation device directly to hospitals and surgical centers to treat obstructive sleep apnea.

INSP’s flags, in plain English

Each flag is a number from Inspire Medical Systems’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Stupid Cash

Can pay this year's bills 6.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 3% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 86.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Profit with Caveats

Bottom-line profit of $101M in the 12 months to Sep 30, 2026, next to $16M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about INSP

How big is Inspire Medical Systems?

Inspire Medical Systems’ market cap is $1.63B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $881.19M: what customers paid the company over the last year, before any costs.

What is INSP’s P/E ratio?

INSP’s P/E ratio is 16.4×. Investors pay about 16.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with INSP?

Revenue relies heavily on a single product platform and requires continuous approvals for insurance reimbursement. That is one risk on Inspire Medical Systems’ card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Inspire Medical Systems’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. INSP’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card